



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/505512/2011

European Medicines Agency decision P/203/2011

of 31 August 2011

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo), (EMA-000065-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/203/2011

of 31 August 2011

on the acceptance of a modification of an agreed paediatric investigation plan for telbivudine (Sebivo), (EMA-000065-PIP01-07-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/111/2008 issued on 1 December 2008, the decision P/119/2010 issued on 9 July 2010,

Having regard to the application submitted by Novartis Europharm Limited on 28 April 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 July 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for telbivudine (Sebivo), film-coated tablet, oral solution, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB, Horsham, United Kingdom.

Done at London, 31 August 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/505512/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000065-PIP01-07-M02

Scope of the application

Active substance(s):

Telbivudine

Invented name:

Sebivo

Condition(s):

Treatment of Chronic Hepatitis B

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Limited

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 28 April 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/111/2008 issued on 1 December 2008, the decision P/119/2010 issued on 9 July 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

The procedure started on 18 May 2011.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 15 July 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of Chronic hepatitis B

The waiver applies to:

- The paediatric population from birth to less than 2 years of age;
- for Oral solution and Film-coated tablet, Oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Chronic hepatitis B

2.1.1. Indication(s) targeted by the PIP

- Treatment of children with HBeAg-positive compensated chronic hepatitis B;
- Treatment of children with HBeAg-negative compensated chronic hepatitis B;

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet for oral use

Oral solution

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Development of an age appropriate formulation for oral use
Non-clinical	2	• Study 1: A 20 days oral (gavage) neonatal and juvenile development dose range-finding study in rats • Study 2: A 10 weeks oral (gavage) study in juvenile rats to evaluate telbivudine effect on the postnatal development
Clinical	4	• Study 3: Open-Label, single-dose study in children and adolescents with Chronic Hepatitis B Virus Infection from 2 to less than 18 years of age to evaluate pharmacokinetics, safety and tolerability of telbivudine • Study 4: Randomised, double-blind, placebo-controlled, multi-centre study to evaluate pharmacokinetics, efficacy and safety of telbivudine in children and adolescents aged from 2 to less than 18

Area	Number of studies	Description
		years with compensated HBeAg-positive chronic hepatitis B virus infection • Study 5: Randomised open label multi-centre study to evaluate efficacy and safety, of telbivudine in children and adolescents with compensated HBeAg-negative chronic hepatitis B virus infection in patients aged from 2 to less than 18 years • Study 6: A cross-sectional, multi-center retrospective data collection study in Western and Asian countries in children and adolescents with chronic hepatitis B virus infection in patients aged from 2-to less than 18 year

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2019
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic hepatitis B

Authorised indications:

Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. See section 5.1 for details of

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/07/388/001	Sebivo	600 mg	Film-coated tablet	Oral use	Blister (PVC/alu)		28 tablets
EU/1/07/388/002	Sebivo	600 mg	Film-coated tablet	Oral use	Blister (PVC/alu)		98 tablets
EU/1/07/388/003	Sebivo	20 mg/mL	Oral solution	Oral use	Bottle (glass)	300 ml (20mg/ml)	1 bottle + 1 cup + 1 oral syringe